EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases
Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. These include new clinical data supporting the efficacy and safety of EYLEA HD® (aflibercept) Injection 8 mg for treating patients with serious retinal diseases.
“New presentations will further highlight the EYLEA HD clinical profile, showcasing its unparalleled durability, while allowing similar efficacy and safety to EYLEA 2 mg, but with fewer injections. This includes the Phase 3 data supporting HD approval in RVO, where its durability offers the first every-two-month treatment option in the setting, prior to which monthly treatment was required with all other anti-VEGF agents,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron.
In addition, while EYLEA HD allows for most patients to achieve longer dosing intervals, data will also be presented from the ELARA trial, supporting HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly EYLEA HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.”
EYLEA HD was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with macular edema following retinal vein occlusion (RVO) based on data from the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks, and provides the first every-two-month treatment option for these patients who previously required more frequent treatment. At Angiogenesis, final, long-term results through the end of the trial (at 64 weeks) will be presented for the first time.
Angiogenesis will also mark the first presentation of full primary data from ELARA, a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks in previously treated patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME). While EYLEA HD allows for most patients to achieve longer dosing intervals, with the best-in-class efficacy and safety seen with (aflibercept) Injection 2 mg, there are a small number of patients who still require monthly treatment even with EYLEA HD.
The ELARA trial supported approval of this monthly option for some patients, while also showing that patients who switched to EYLEA HD from other anti-VEGF treatments generally improved their visual acuity while also achieving better anatomic control of retinal swelling.
The most common adverse reactions (≥3%) reported in patients treated with HD across approved indications were cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment and vitreous floaters.
The full list of Regeneron presentations at Angiogenesis:
| Presentation title | Presenter | Presentation time (EST) |
| Correlation of Foveal Invasion with Visual Function at Baseline in the Regeneron SIENNA Geographic Atrophy C5 Inhibitor Trial | Glenn J. Jaffe | 11:20am |
| Safety and Efficacy of Aflibercept 8 mg in Patients With nAMD or DME: Primary Results from the Phase 3b ELARA Trial | David M. Brown | 4:45pm |
| Aflibercept 8mg in Retinal Vein Occlusion: Final Results from the QUASAR Study* | Varun Chaudhary | 4:55pm |
| Safety Profile of Aflibercept 8 mg: A Pooled Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials | John A. Wells | 5:05pm |
*Bayer-run trial
About EYLEA HD
Over a decade ago, Regeneron introduced EYLEA, a vascular endothelial growth factor inhibitor, and transformed the treatment paradigm for certain serious chorioretinal vascular diseases. With a well-established efficacy and consistent safety profile from 16 pivotal trials, EYLEA is approved to treat vision-threatening conditions that impact patients from their earliest days, such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO) and wet age-related macular degeneration (wAMD).
Pushing the boundaries of science further to meet patient needs, EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to treat patients with wAMD, DME, DR and RVO.
EYLEA HD is being jointly developed by Regeneron and Bayer AG. Regeneron maintains exclusive rights to HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and EYLEA HD.
About Ophthalmology Development at Regeneron
At Regeneron, we relentlessly pursue groundbreaking innovations in eye care science to help maintain the eye health of the millions of Americans impacted by vision-threatening conditions. Our expertise in angiogenesis and decades of research serve as our foundation, fueling our ongoing ambition to further innovate new solutions for patients. Our robust and diverse research and development program in ophthalmology includes efforts to potentially address additional serious eye diseases. This includes the ongoing Phase 3 SIENNA clinical trial in geographic atrophy, as well as additional novel candidates for uveitis, glaucoma and thyroid eye disease.
Source Link: https://investor.regeneron.com/
